Not for distribution to U.S. Newswire Services or for dissemination in the United States.

INDIVA

INDIVA Provides Update on DeepCell™ Industries Partnership

LONDON, ON – June 6, 2018: INDIVA Limited (the “Company” or “INDIVA”) (TSX- V:NDVA) is pleased to announce  it has obtained conditional approval of the TSX Venture Exchange (the “Exchange“) in respect of its previously announced exclusive license agreement with DeepCell Industries (“DeepCell“), a Seattle based technology development company focusing on material science, microfluidics and cannabinoid molecule discoveries.

As previously announced by way of press release on April 26, 2018, under the license agreement (the “License“), DeepCell has granted INDIVA the exclusive license to manufacture and sell DeepCell’s complete line of products, including its cannabis infused products marketed under the “Ruby” brand produced using DeepCell’s patented Crystal Fusion™ technology, and cannabis wellness products. DeepCell’s patented Crystal Fusion™ technology mechanically fuses cannabinoids with sugar or salt, creating crystals that are both water soluble and stable (i.e. do not oxidize).

Subject to applicable regulatory approvals, INDIVA will participate in product innovations from DeepCell and work with DeepCell to provide revolutionary cannabis edibles to Canadian consumers. The License marks the first step in INDIVA’s strategy to offer high quality innovative cannabis edibles in Canada when the law evolves to permit such offerings.

INDIVA and DeepCell will also collaborate to introduce DeepCell’s innovative and wellness focused products to international markets, subject to applicable regulatory approvals.  INDIVA does not anticipate completing its previously announced equity investment in DeepCell until applicable regulatory approvals for such investment are obtained.

 

Contact Information

INDIVA

Susan Mutterback, Public Relations
519-649-6686 x227
[email protected]

Koby Smutylo, COO and General Counsel
613-869-5440
[email protected]

Niel Marotta, CEO and President
613-883-8541
[email protected]

 

About DeepCell Industries

DeepCell Industries is a Seattle-based technology development company focusing on material science, microfluidics, and cannabinoid molecule discoveries. DeepCell has pioneered the use of Crystal Fusion™ process as their first commercially-ready nanotechnology available for license. Ruby Cannabis Sugar™ has been named a Dope Magazine “Product We Love,” and “high-quality and discreet” by Culture Magazine.

 

About INDIVA

INDIVA is a Canadian supplier of high quality, medical grade cannabis. INDIVA’s strain selection, cultivation and client care processes combine the know-how and experience of an internationally recognized and award-winning grow-team with GMP-compliant quality assurance standard operating procedures.

INDIVA aims to become a global marijuana brand recognized for high quality cannabis products and excellent client care. As marijuana laws liberalize in Canada, INDIVA will expand its product offering to include safe edibles and other client-friendly cannabis products. In addition, as marijuana laws liberalize internationally, INDIVA will use its Canadian operations as a platform to open new markets for its cannabis products.

 

DISCLAIMER & READER ADVISORY

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the Transaction and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the License, future international expansion, future product offerings, future entry into additional markets, changes to laws and regulations in Canada and internationally, and compliance with applicable regulations, including those of the Exchange. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to obtain the necessary corporate, regulatory and other third parties approvals; licensing and other risks associated with regulated ACMPR entities; and completion of satisfactory due diligence. The forward looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.